Kripthonite Therapeutics targets cancer cells, resilient to traditional treatments. Their therapy disrupts the cells' energy metabolism, swiftly eliminating them, rendering tumors susceptible to other treatments. The lead candidate PH1154 enhances radiation therapy effectiveness, showcasing groundbreaking potential in eliminating resilient cancer cells, thus enhancing overall treatment efficacy.
Established in 2023.
